



PRIOR AUTHORIZATION REQUEST

Somavert

Patient Information:

Name:	
Member ID:	
Address:	
City, State, Zip:	
Date of Birth:	

Prescriber Information:

Name:	
NPI:	
Phone Number:	
Fax Number:	
Address:	
City, State, Zip:	

Requested Medication

Rx Name:	
Rx Strength:	
Rx Quantity:	
Rx Frequency:	
Rx Route of Administration:	
Diagnosis and ICD Code:	

Your patient's prescription benefit requires that we review certain requests for coverage with the prescriber. You have prescribed a medication for your patient that requires Prior Authorization before benefit coverage or coverage of additional quantities can be provided. Please complete the following questions then fax this form to the toll-free number listed below. Upon receipt of the completed form, prescription benefit coverage will be determined based on the plan's rules.

SECTION A: Please note that supporting clinical documentation is required for ALL PA requests. Pharmacy prior authorization reviews can be subject to trial with additional medications that are not listed within the criteria. The policies are subject to change based on COMAR requirements, MDH transmittals and updates to treatment guidelines.

- | | |
|---|--|
| 1 | What is the diagnosis or indication?
<input type="checkbox"/> Acromegaly (If checked, go to 2)

<input type="checkbox"/> Treatment of excess growth hormone associated with McCune-Albright syndrome (MAS)
(If checked, no further questions)

<input type="checkbox"/> Other (If checked, no further questions) |
| 2 | Is this medication being prescribed by, or in consultation with, an endocrinologist? Yes No |

If you have any
questions, call:
1-888-258-8250

Version 07.2025

PRIOR AUTHORIZATION REQUEST

[If no, no further questions.]

- | | | | |
|----|---|-----|----|
| 3 | Is this a request for INITIAL or CONTINUATION of therapy with the requested medication?
<input type="checkbox"/> Initial (If checked, go to 4)

<input type="checkbox"/> Continuation (If checked, go to 13) | | |
| 4 | Is the patient 18 years of age or older?
[If no, no further questions.] | Yes | No |
| 5 | Has the patient had an inadequate response to surgery and/or radiotherapy?
[If yes, skip to question 8.] | Yes | No |
| 6 | Is the patient an appropriate candidate for surgery and/or radiotherapy?
[If no, skip to question 8.] | Yes | No |
| 7 | Is the patient experiencing negative effects due to tumor size (for example, optic nerve compression)?
[If no, no further questions.] | Yes | No |
| 8 | Does the patient have a pre-treatment (baseline) insulin-like growth factor-1 (IGF-1) level greater than 2 times the upper limit of normal (ULN) based on age and gender for the reporting laboratory?
[NOTE: Pre-treatment (baseline) refers to the IGF-1 level prior to the initiation of any somatostatin analog (for example, Mycapssa (octreotide delayed-release capsules), an octreotide acetate injection product (for example, Bynfezia Pen, Sandostatin [generics], Sandostatin LAR Depot), Signifor LAR [pasireotide for injectable suspension], Somatuline Depot [lanreotide subcutaneous injection]), dopamine agonist (for example, cabergoline, bromocriptine), or Somavert (pegvisomant for injection). Reference ranges for IGF-1 vary among laboratories.]
[If no, no further questions.] | Yes | No |
| 9 | Does the patient's insulin like growth factor-1 (IGF-1) remain elevated despite a 6 month trial of maximally tolerated dose of cabergoline?
[If yes, skip to question 11.] | Yes | No |
| 10 | Does the patient have a contraindication or intolerance to cabergoline?
[If no, no further questions.] | Yes | No |
| 11 | Has the patient tried and failed, or have an intolerance or contraindication to Sandostatin LAR?
[If no, no further questions.] | Yes | No |
| 12 | Does the patient have baseline liver function tests (LFTs) that are LESS THAN 3 times the upper limit of normal?
[No further questions.] | Yes | No |

**If you have any
questions, call:
1-888-258-8250**

Version 07.2025



PRIOR AUTHORIZATION REQUEST

13	Has the patient responded to therapy with the requested medication, which is defined as having decreased or normalized insulin like growth factor-1 (IGF-1) levels? ACTION REQUIRED: Submit supporting documentation.	Yes	No
----	---	-----	----

Please document the diagnoses, symptoms, and/or any other information important to this review:

SECTION B: Physician Signature

PHYSICIAN SIGNATURE

DATE

FAX COMPLETED FORM TO: 1-833-896-0656

Disclaimer: An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

Confidentiality: The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use, distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.

If you have any
questions, call:
1-888-258-8250

Version 07.2025